MX9701685A - Nuevos derivados de bencimidazol que tienen la actividad de inhibicion de la fosfodiestearasa cgmp. - Google Patents

Nuevos derivados de bencimidazol que tienen la actividad de inhibicion de la fosfodiestearasa cgmp.

Info

Publication number
MX9701685A
MX9701685A MX9701685A MX9701685A MX9701685A MX 9701685 A MX9701685 A MX 9701685A MX 9701685 A MX9701685 A MX 9701685A MX 9701685 A MX9701685 A MX 9701685A MX 9701685 A MX9701685 A MX 9701685A
Authority
MX
Mexico
Prior art keywords
group
benzimidazole derivatives
phosphodisterase
cgmp
inhibiting activity
Prior art date
Application number
MX9701685A
Other languages
English (en)
Inventor
Takao Nishi
Seiji Sato
Takeshi Nagatani
Hirotaka Yukawa
Noboyuki Koga
Masahiro Saito
Shinji Yoshinaga
Original Assignee
Otsuka Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharma Co Ltd filed Critical Otsuka Pharma Co Ltd
Publication of MX9701685A publication Critical patent/MX9701685A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cardiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Measuring Volume Flow (AREA)

Abstract

La presente invencion proporciona los nuevos derivados de bencimidazol o las sales de éstos representados por la formula general (I) en donde R1 es unátomo de halogeno; R2 es un grupo fenil-alquilo inferior, R3 es un grupo heterocíclico seleccionado del grupo 2(1H)-quinolinonilo, grupo 3, 4-benzoxazinilo; A es un grupo alquileno inferior; n es 0 o 1. Los derivados de bencimidazol o las sales de la presente invencion son agentes efectivos para el tratamiento de varias enfermedades arterioescleroticas.
MX9701685A 1995-07-07 1996-07-03 Nuevos derivados de bencimidazol que tienen la actividad de inhibicion de la fosfodiestearasa cgmp. MX9701685A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP17180795 1995-07-07
PCT/JP1996/001841 WO1997003070A1 (en) 1995-07-07 1996-07-03 Novel benzimidazole derivatives having cgmp-phosphodisterase inhibiting activity

Publications (1)

Publication Number Publication Date
MX9701685A true MX9701685A (es) 1997-06-28

Family

ID=15930095

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9701685A MX9701685A (es) 1995-07-07 1996-07-03 Nuevos derivados de bencimidazol que tienen la actividad de inhibicion de la fosfodiestearasa cgmp.

Country Status (16)

Country Link
US (1) US5998437A (es)
EP (1) EP0779887B1 (es)
KR (1) KR100231639B1 (es)
CN (1) CN1074413C (es)
AR (1) AR002690A1 (es)
AT (1) ATE201407T1 (es)
AU (1) AU703073B2 (es)
DE (1) DE69612949T2 (es)
DK (1) DK0779887T3 (es)
ES (1) ES2159036T3 (es)
GR (1) GR3036420T3 (es)
HK (1) HK1003436A1 (es)
MX (1) MX9701685A (es)
PT (1) PT779887E (es)
TW (1) TW381092B (es)
WO (1) WO1997003070A1 (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6410584B1 (en) 1998-01-14 2002-06-25 Cell Pathways, Inc. Method for inhibiting neoplastic cells with indole derivatives
EP1120120A4 (en) * 1998-10-05 2009-04-29 Eisai R&D Man Co Ltd TABLETS DISSOLVING DIRECTLY IN MOUTH
US6200771B1 (en) 1998-10-15 2001-03-13 Cell Pathways, Inc. Method of using a novel phosphodiesterase in pharmaceutical screeing to identify compounds for treatment of neoplasia
US6133271A (en) * 1998-11-19 2000-10-17 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure thienopyrimidine derivatives
US6187779B1 (en) 1998-11-20 2001-02-13 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to 2,8-disubstituted quinazoline derivatives
US6369092B1 (en) 1998-11-23 2002-04-09 Cell Pathways, Inc. Method for treating neoplasia by exposure to substituted benzimidazole derivatives
US6486155B1 (en) 1998-11-24 2002-11-26 Cell Pathways Inc Method of inhibiting neoplastic cells with isoquinoline derivatives
US6034099A (en) * 1998-11-24 2000-03-07 Cell Pathways, Inc. Method for inhibiting neoplastic lesions by administering 4-(arylmethylene)- 2, 3- dihydro-pyrazol-3-ones
US6077842A (en) * 1998-11-24 2000-06-20 Cell Pathways, Inc. Method of inhibiting neoplastic cells with pyrazolopyridylpyridazinone derivatives
US6020379A (en) * 1999-02-19 2000-02-01 Cell Pathways, Inc. Position 7 substituted indenyl-3-acetic acid derivatives and amides thereof for the treatment of neoplasia
JP2003522760A (ja) * 2000-02-09 2003-07-29 ザ プロクター アンド ギャンブル カンパニー ２−フェニルカルバモイル−ベンジミダゾール類
EP1419770A4 (en) * 2001-08-24 2005-08-03 Shionogi & Co AGENT ACC L RATION OF THE EXPRESSION OF APO AI
US7208516B2 (en) 2002-03-20 2007-04-24 Celgene Corporation Methods of the treatment of psoriatic arthritis using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
US7893101B2 (en) 2002-03-20 2011-02-22 Celgene Corporation Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
US6962940B2 (en) 2002-03-20 2005-11-08 Celgene Corporation (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
US7276529B2 (en) 2002-03-20 2007-10-02 Celgene Corporation Methods of the treatment or prevention of exercise-induced asthma using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
US7087790B2 (en) * 2003-08-29 2006-08-08 Rutgers, The State University Of New Jersey Benzotropolone derivatives and modulation of inflammatory response
EP1742637A4 (en) * 2004-04-23 2011-06-08 Paratek Pharm Innc TRANSCRIPTION FACTOR MODULATION COMPOUNDS AND METHODS OF USE
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
US20090299067A1 (en) * 2008-05-30 2009-12-03 Pagoria Philip F New synthesis of 2,6-diamino-3,5-dinitropyrazine-1-oxide from 2,6-diaminopyrazine-1-oxide
EP2844247A4 (en) * 2012-04-20 2015-11-25 Anderson Gaweco ROR MODULATORS AND ITS USES
ES2749433T3 (es) 2014-06-23 2020-03-20 Celgene Corp Apremilast para el tratamiento de una enfermedad hepática o una anomalía de la función hepática
AU2015295405B2 (en) * 2014-08-01 2020-04-09 Nuevolution A/S Compounds active towards bromodomains
KR102501049B1 (ko) 2021-12-20 2023-02-20 김학용 전복 양식 쉘터용 친환경 패널 및 그 친환경 쉘터와 이를 이용한 전복양식설비

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59148051A (ja) * 1983-02-14 1984-08-24 Fuji Photo Film Co Ltd ハロゲン化銀写真感光材料
JPS61167952A (ja) * 1985-01-21 1986-07-29 Fuji Photo Film Co Ltd 多層ハロゲン化銀カラ−写真感光材料
JPH0749405B2 (ja) * 1985-12-26 1995-05-31 三共株式会社 レニン阻害ペプチド類似体
JPH0784462B2 (ja) * 1986-07-25 1995-09-13 日清製粉株式会社 ベンゾイミダゾ−ル誘導体
US4851423A (en) * 1986-12-10 1989-07-25 Schering Corporation Pharmaceutically active compounds
JPH0820699B2 (ja) * 1987-10-08 1996-03-04 富士写真フイルム株式会社 直接ポジカラー写真感光材料
US4994477A (en) * 1988-03-24 1991-02-19 Abbott Laboratories Heterocyclic renin inhibitors
JP2869561B2 (ja) * 1989-05-22 1999-03-10 大塚製薬株式会社 血小板粘着抑制剤
KR920701167A (ko) * 1989-07-07 1992-08-11 에릭 에스. 딕커 약제학적 활성 화합물
US5098924A (en) * 1989-09-15 1992-03-24 E. R. Squibb & Sons, Inc. Diol sulfonamide and sulfinyl renin inhibitors
MX9200299A (es) * 1991-02-07 1992-12-01 Roussel Uclaf Nuevos derivados biciclicos nitrogenados, su procedimiento de preparacion los nuevos compuestos intermedios obtenidos su aplicacion como medicamentos y las composiciones farmaceuticas que los contienen.
PT100905A (pt) * 1991-09-30 1994-02-28 Eisai Co Ltd Compostos heterociclicos azotados biciclicos contendo aneis de benzeno, ciclo-hexano ou piridina e de pirimidina, piridina ou imidazol substituidos e composicoes farmaceuticas que os contem
GB9121776D0 (en) * 1991-10-14 1991-11-27 Fujisawa Pharmaceutical Co Benzimidazole derivatives and process for preparation thereof
PH31122A (en) * 1993-03-31 1998-02-23 Eisai Co Ltd Nitrogen-containing fused-heterocycle compounds.
JPH07133224A (ja) * 1993-11-10 1995-05-23 Kyowa Hakko Kogyo Co Ltd 動脈硬化治療薬

Also Published As

Publication number Publication date
EP0779887B1 (en) 2001-05-23
AU6318196A (en) 1997-02-10
TW381092B (en) 2000-02-01
US5998437A (en) 1999-12-07
DE69612949T2 (de) 2001-09-20
EP0779887A1 (en) 1997-06-25
ES2159036T3 (es) 2001-09-16
KR100231639B1 (ko) 1999-11-15
WO1997003070A1 (en) 1997-01-30
GR3036420T3 (en) 2001-11-30
AU703073B2 (en) 1999-03-11
PT779887E (pt) 2001-08-30
HK1003436A1 (en) 1998-10-30
KR970705559A (ko) 1997-10-09
DK0779887T3 (da) 2001-11-26
AR002690A1 (es) 1998-03-25
ATE201407T1 (de) 2001-06-15
CN1074413C (zh) 2001-11-07
CN1158129A (zh) 1997-08-27
DE69612949D1 (de) 2001-06-28

Similar Documents

Publication Publication Date Title
MX9701685A (es) Nuevos derivados de bencimidazol que tienen la actividad de inhibicion de la fosfodiestearasa cgmp.
HUP0001054A2 (hu) IV-típusú foszfodiészteráz inhibitor 1-aril-1,8-naftiridin-4-on-származékok
MX9800577A (es) Derivados de 4,5-diaril oxazol.
DE69634254D1 (de) Verwendung von oxidosqualencyclasehemmer zur senkung des cholesterinblutspiegels
ATE188472T1 (de) 4-arylmethyloxymethyl piperidine als tachykinin antagonisten
DE69719350T2 (de) 2-pyrimidinamin derivaten und verfahrens zu deren herstellung
ES2147836T3 (es) Derivados de 4,5-diariloxazol.
NO971538L (no) Purin- og guaninforbindelser som inhibitorer for PNP
FI952424A0 (fi) 11,21-bisfenyyli-19-norpregaanijohdannaisia
MX9800718A (es) Derivados de 2-(4-substituidos)-bencilamino-2-metil- propanamida.
NO20022232L (no) Imidazolforbindelser for anvendelse som inhibitorer for fosfodiesterase VII
ID26622A (id) Senyawa-senyawa pengganti 2-benzylamino-2-phenyl-acetamide
ES2191341T3 (es) Derivados de la 2-fenoxianilina.
IT1196423B (it) Benzotiazolin-composti
DE69813554D1 (de) Cyclische harnstoff- und lactamderivate von benzo(5,6)cycloheptapyridinen zur verwendung als farnesyl-protein-transferase-hemmer
CA2198266A1 (en) Novel benzimidazole derivatives
ES8506002A1 (es) Procedimiento para la obtencion de 2-(1-indolinil-metil)-imidazolinas
DE69017627T2 (de) Isochinolinderivate und ihre Salze als Proteasehemmer.
ATE138373T1 (de) N,n',n'-trisubstituierte-5-bisaminomethylen-1,3 dioxan-4,6-dione als acyl-coa:cholesterol- acyltransferasehemmer
ES2206296T3 (es) Derivados de tienopiranocarboxamida.
MX9603868A (es) Composicion farmaceutica de derivados de indeno para la regulacion de la apoptosis.
DE60009301D1 (en) Benzimidazolverbindungen
ATE188468T1 (de) Antiherpetische peptidomimetische verbindungen
NO944762L (no) Nye 3-okso-1,4-benzotiazinderivater

Legal Events

Date Code Title Description
FG Grant or registration
MM Annulment or lapse due to non-payment of fees